尿激酶联合缬沙坦对IgA肾病尿检异常型的疗效分析

目的小剂量尿激酶联合缬沙坦治疗IgA肾病尿检异常型的临床疗效。方法将60例经肾脏组织活体检查并结合临床诊断为原发性IgA肾病尿检异常的患者，分为尿激酶联合缬沙坦治疗组（治疗组）和单用缬沙坦治疗组（对照组），每组各30例。比较2组的临床疗效。结果治疗组尿红细胞（RBC）计数与24h尿蛋白定量在第3、6及12个月均较治疗前明显下降（P〈0.05），而对照组尿RBC计数与24h尿蛋白定量在治疗前后比较虽有下降，但无统计学意义（P〉0.05）。结论通过尿激酶联合缬沙坦治疗，能有效减少IgA肾病尿检异常患者的蛋白尿和镜下血尿。

Effect of combined urokinase with valsartan in the treatment of IgA nephropathy

Objective To evaluate the effect of urokinase combined with valsartan treating IgA nephropathy with asymptom abnormal urinalysis. Methods Sixty patients who underwent renal biopsy and diagnosed as IgA nephropathy before enrolment in the study were randomly divided into two groups. Thirty patients received the combined urokinase with valsartan treatment, and the rest 30 patients received simple valsartan treatment. Results At the 3rd,6th,and 12th month after treatment, the hematuria and proteinuria were significantly decreased in the combined treatment group （P〈0.05）. In the control group, at the 12th month after treatment,the hematuria and proteinria were decreased much slowly. Conclusion Combined regime of urokinase and valsartan was effective and safe in treating IgA nephropathy with asymptom abnormal urinalysia by deceasing proteinuria, and hematuria.